Study guide
8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations
Philippine Medical Technologists Licensure Examination MTLE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety
1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards
2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function
2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice
3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology
3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology
4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety
4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms
5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria
5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology
6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology
6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods
7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods
7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control
8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders
8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry
9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders
9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests
10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing
10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures
11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions
11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin
12 Chapter 12: Clinical Serology and Immunology
12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)
13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology
13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control
14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens
14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens
15 Chapter 15: Histopathologic Techniques and Cytotechnology
15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records
16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics
16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics
8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations
Key Takeaways Explain This Topic AI
Granulopoiesis undergoes a defined maturation sequence where promyelocytes are characterized by primary azurophilic granules containing myeloperoxidase, and myelocytes mark both the first appearance of secondary lineage-specific granules and the final stage capable of mitotic division.
The sepsis toxic triad in neutrophils comprises toxic granulation (persisting primary granules with high mucosubstance), Döhle bodies (lamellar aggregates of rough endoplasmic reticulum), and toxic vacuolation (phagocytic digestive vacuoles from bacterial lysis).
A leukemoid reaction is differentiated from Chronic Myeloid Leukemia (CML) by a markedly elevated Leukocyte Alkaline Phosphatase (LAP) score (>100), prominent toxic changes, absence of absolute basophilia, and absence of the BCR-ABL1 Philadelphia chromosome.
Inherited leukocyte anomalies exhibit distinct morphologic and molecular defects: Pelger-Huët (LBR mutation, hyposegmented pince-nez nuclei), May-Hegglin (MYH9 mutation, spindle Döhle-like inclusions and giant platelets), Chédiak-Higashi (LYST mutation, giant lysosomal granules and albinism), and Alder-Reilly (mucopolysaccharidosis, coarse purple azurophilic granules across all lineages).
Last updated: October 2026
Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations
Leukocytes (white blood cells) are the cellular mediators of innate and adaptive immunity. In the clinical diagnostic hematology laboratory, automated differential counters screen leukocyte populations, but microscopic review of the peripheral blood smear remains the gold standard for recognizing reactive toxic responses, cellular atypia, inherited anomalies, and hematologic malignancies. MTLE candidates must possess an exhaustive understanding of granulopoietic developmental milestones, reactive alterations vs neoplastic proliferation, and differential diagnosis of non-malignant leukocyte disorders.
1. Normal Granulopoiesis, Monocytopoiesis, and Lymphopoiesis
Granulopoiesis is the developmental sequence producing mature neutrophils, eosinophils, and basophils within the bone marrow. Total developmental transit time from myeloblast to functional segmented neutrophil is approximately 10 to 14 days . GRANULOPOIETIC MATURATION SEQUENCE
- ┌──────────────┐ ┌──────────────┐ ┌──────────────┐
- │ Myeloblast │ ──> │ Promyelocyte │ ──> │ Myelocyte │
- └──────────────┘ └──────────────┘ └──────┬───────┘
- 15-20 µm 16-25 µm │ 12-18 µm
- Delicate chrom 1° azurophilic │ 2° specific granules
- 2-5 nucleoli granules (MPO) │ [LAST MITOTIC STAGE]
- Perinuclear hof ▼
- ┌──────────────┐
- ┌──────────────┐ ┌──────────────┐ │Metamyelocyte │
- │ Segmented │ <── │Band Neutrophil<─── │ │
- │ Neutrophil │ │ │ │ │
- └──────────────┘ └──────────────┘ └──────────────┘
- 10-15 µm 10-15 µm 10-15 µm
- 2-5 lobes C/horseshoe shape Kidney indentation
- Chromatin filament Parallel margins < 50% nuclear diameter
- 1. Myeloblast
Size and N : C N:C N : C Ratio : 15 – 20 μ m 15\text{--}20\ \mu\text{m} 15 – 20 μ m in diameter; high N : C ratio ( 4 : 1 to 5 : 1 ) N:C\text{ ratio } (4:1\text{ to }5:1) N : C ratio ( 4 : 1 to 5 : 1 ) .
Nucleus : Round to oval, centrally placed, with smooth nuclear membrane. Delicate, finely dispersed, lacy, sieve-like euchromatin. Contains 2 to 5 distinct, pale round nucleoli .
Cytoplasm : Moderate basophilic cytoplasm without granules ( Type I Myeloblast ), or containing fewer than 20 fine azurophilic granules ( Type II Myeloblast ).
2. Promyelocyte (Progranulocyte)
Size : 16 – 25 μ m 16\text{--}25\ \mu\text{m} 16 – 25 μ m in diameter (often the largest cell in the granulocytic series).
Nucleus : Round to oval, slightly eccentric. Chromatin begins subtle condensation, but nucleoli remain visible.
Cytoplasm : Distinctive for the burst of Primary (Azurophilic / Non-Specific) Granules . These granules are large, reddish-purple to dark blue, and contain Myeloperoxidase (MPO) , lysozyme, acid phosphatase, elastase, defensins, and chloroacetate esterase. A prominent pale, ungranulated perinuclear clear zone (hof) representing the enlarged Golgi apparatus is characteristic.
3. Myelocyte
Size : 12 – 18 μ m 12\text{--}18\ \mu\text{m} 12 – 18 μ m in diameter ( N : C ratio 2 : 1 to 1 : 1 N:C\text{ ratio } 2:1\text{ to }1:1 N : C ratio 2 : 1 to 1 : 1 ).
Nucleus : Round, oval, or flattened on one side, located eccentrically. Chromatin is coarser and more condensed; nucleoli are absent.
Cytoplasm : Defined by the FIRST APPEARANCE OF SECONDARY (SPECIFIC) GRANULES in the Golgi region ("dawn of neutrophilia"). Secondary granules are fine, sand-like, pink-tan/salmon in neutrophils; large, round, bright red-orange refractive granules in eosinophils; and large, dark purple-black soluble granules in basophils. Secondary neutrophilic granules contain lactoferrin , collagenase, transcobalamin I, and alkaline phosphatase.
CRITICAL MILESTONE : The myelocyte is the FINAL MATURATION STAGE CAPABLE OF CELL DIVISION (MITOSIS) .
4. Metamyelocyte
Size : 10 – 15 μ m 10\text{--}15\ \mu\text{m} 10 – 15 μ m in diameter ( N : C ratio 1.5 : 1 N:C\text{ ratio } 1.5:1 N : C ratio 1.5 : 1 ).
Nucleus : Characterized by an indented, kidney-bean-shaped nucleus . By definition, the depth of nuclear indentation is less than 50% of the theoretical diameter of a round nucleus . Chromatin is heavily clumped, patchy, and condensed. Incapable of mitosis.
Cytoplasm : Packed with secondary specific granules; primary granules are still present but are largely obscured.
5. Band Neutrophil (Stab Cell)
Size : 10 – 15 μ m 10\text{--}15\ \mu\text{m} 10 – 15 μ m in diameter.
Nucleus : Elongated, curved, horseshoe-, C-, or S-shaped nucleus. The indentation exceeds 50% of the width of a hypothetical round nucleus, but the nuclear margins remain parallel, and distinct lobes are not separated by a filament . Visible chromatin pattern must be discernible within the connecting bridge between potential lobes.
Cytoplasm : Pink-tan cytoplasm filled with secondary granules.
6. Segmented Neutrophil (PMN)
Size : 10 – 15 μ m 10\text{--}15\ \mu\text{m} 10 – 15 μ m in diameter.
Nucleus : Polymorphonuclear with 2 to 5 distinct lobes connected by a delicate, thread-like, hair-like chromatin filament devoid of any visible internal chromatin pattern.
Cytoplasm : Abundant pink-to-tan cytoplasm containing thousands of specific secondary and tertiary (gelatinase) granules.
Monocytopoiesis and Lymphopoiesis
Monocyte Development : Monoblast → \to → Promonocyte → \to → Mature Monocyte ( 12 – 20 μ m 12\text{--}20\ \mu\text{m} 12 – 20 μ m ). Mature monocytes feature an indented, folded, or brain-like convoluted lobulated nucleus with delicate, loose, spongy, "raked" chromatin. Cytoplasm is abundant, opaque gray-blue ("ground-glass") , containing fine, dust-like lilac azurophilic granules and frequent phagocytic digestive vacuoles.
Lymphocyte Development : Lymphoblast → \to → Prolymphocyte → \to → Mature Lymphocyte ( 7 – 12 μ m 7\text{--}12\ \mu\text{m} 7 – 12 μ m ). Characterized by a round to slightly indented nucleus with dense, heavily clumped, block-like heterochromatin (checkerboard), a high N : C N:C N : C ratio, and a narrow rim of sky-blue cytoplasm. Large granular lymphocytes (LGLs; NK cells and cytotoxic T-cells) feature abundant pale cytoplasm with sparse, discrete azurophilic granules.
2. Quantitative Reference Intervals and Absolute Counts
In clinical hematology, evaluating white blood cells requires converting relative percentages into Absolute Leukocyte Counts :
Absolute Count ( × 10 9 / L ) = Total WBC Count ( × 10 9 / L ) × ( Relative Percentage 100 ) \text{Absolute Count } (\times 10^9/\text{L}) = \text{Total WBC Count } (\times 10^9/\text{L}) \times \left( \frac{\text{Relative Percentage}}{100} \right) Absolute Count ( × 1 0 9 / L ) = Total WBC Count ( × 1 0 9 / L ) × ( 100 Relative Percentage )
Clinical decisions must never be made on relative percentages alone (e.g., relative neutropenia can occur in a patient with severe leukocytosis who actually has absolute neutrophilia).
Leukocyte Parameter Relative Percentage (%) Absolute Reference Interval (Adults)
Total White Blood Cell Count — 4.5 to 11.0 × 10 9 / L 4.5\text{ to }11.0 \times 10^9/\text{L} 4.5 to 11.0 × 1 0 9 / L ( 4 , 500 – 11 , 000 / μ L 4,500\text{--}11,000/\mu\text{L} 4 , 500 – 11 , 000/ μ L )
Segmented Neutrophils 40 % to 70 % 40\%\text{ to }70\% 40% to 70% 1.8 to 7.0 × 10 9 / L 1.8\text{ to }7.0 \times 10^9/\text{L} 1.8 to 7.0 × 1 0 9 / L ( 1 , 800 – 7 , 000 / μ L 1,800\text{--}7,000/\mu\text{L} 1 , 800 – 7 , 000/ μ L )
Band Neutrophils 0 % to 5 % 0\%\text{ to }5\% 0% to 5% 0.0 to 0.5 × 10 9 / L 0.0\text{ to }0.5 \times 10^9/\text{L} 0.0 to 0.5 × 1 0 9 / L ( 0 – 500 / μ L 0\text{--}500/\mu\text{L} 0 – 500/ μ L )
Lymphocytes 20 % to 40 % 20\%\text{ to }40\% 20% to 40% 1.0 to 4.0 × 10 9 / L 1.0\text{ to }4.0 \times 10^9/\text{L} 1.0 to 4.0 × 1 0 9 / L ( 1 , 000 – 4 , 000 / μ L 1,000\text{--}4,000/\mu\text{L} 1 , 000 – 4 , 000/ μ L )
Monocytes 2 % to 10 % 2\%\text{ to }10\% 2% to 10% 0.1 to 1.0 × 10 9 / L 0.1\text{ to }1.0 \times 10^9/\text{L} 0.1 to 1.0 × 1 0 9 / L ( 100 – 1 , 000 / μ L 100\text{--}1,000/\mu\text{L} 100 – 1 , 000/ μ L )
Eosinophils 1 % to 5 % 1\%\text{ to }5\% 1% to 5% 0.0 to 0.5 × 10 9 / L 0.0\text{ to }0.5 \times 10^9/\text{L} 0.0 to 0.5 × 1 0 9 / L ( 0 – 500 / μ L 0\text{--}500/\mu\text{L} 0 – 500/ μ L )
Basophils 0 % to 2 % 0\%\text{ to }2\% 0% to 2% 0.0 to 0.2 × 10 9 / L 0.0\text{ to }0.2 \times 10^9/\text{L} 0.0 to 0.2 × 1 0 9 / L ( 0 – 200 / μ L 0\text{--}200/\mu\text{L} 0 – 200/ μ L )
3. Reactive Leukocyte Alterations: Sepsis Triad and Atypical Lymphocytes
Reactive leukocyte changes represent non-malignant phenotypic modifications induced by systemic inflammation, severe bacterial infection, tissue necrosis, or viral challenge.
The Sepsis Triad of Neutrophil Toxic Changes
During severe acute bacterial infections, septicemia, or burn injury, cytokine release (G-CSF, TNF- α \alpha α ) accelerates bone marrow granulocyte maturation and release, producing three classic toxic morphologic abnormalities: THE NEUTROPHIL TOXIC TRIAD
- ┌───────────────────────┐ ┌───────────────────────┐ ┌───────────────────────┐
- │ TOXIC GRANULATION │ │ DÖHLE BODIES │ │ TOXIC VACUOLATION │
- └───────────┬───────────┘ └───────────┬───────────┘ └───────────┬───────────┘
- │ │ │
- ▼ ▼ ▼
- Dark, coarse, purple- • Pale blue-gray oval • Clear, round, unstained
blue primary granules. peripheral inclusions. phagocytic vacuoles.
• Retained primary • Lamellar aggregates • Active bacterial
azurophilic granules of rough endoplasmic ingestion / autolysis.
rich in mucosubstance. reticulum (rER) and RNA. • Marker of sepsis.
Toxic Granulation : Coarse, prominent, dark purple-blue granules distributed throughout the cytoplasm of mature segmented neutrophils and bands. Pathophysiologically, these represent primary azurophilic granules that retain abnormal mucosubstance and dye-binding affinity due to premature, hurried maturation.
Döhle Bodies : Single or multiple small ( 1 – 2 μ m 1\text{--}2\ \mu\text{m} 1 – 2 μ m ), round or oval, pale light blue-gray cytoplasmic inclusions typically situated near the outer periphery of neutrophils. Biochemically, they represent lamellar aggregates of rough endoplasmic reticulum (rER) and residual ribosomal RNA that failed to mature. Also observed in normal pregnancy and severe trauma.
Toxic Vacuolation : Round, clear, unstained circular vacuoles in neutrophil cytoplasm. Represents secondary lysosomes and phagosomes formed during active phagocytosis and enzymatic autolysis of ingested bacteria. Toxic vacuolation is the most specific morphologic indicator of true bacteremia and severe sepsis.
Reactive / Atypical Lymphocytes (Downey Cells)
Reactive lymphocytes are antigen-stimulated, immunocompetent cells (predominantly CD8+ cytotoxic T-lymphocytes ) reacting to viral pathogens, most notably Epstein-Barr Virus (EBV) causing Infectious Mononucleosis, as well as Cytomegalovirus (CMV), viral hepatitis, and toxoplasmosis.
Downey Classification :
Downey Type I (Plasmacytoid Lymphocyte) : Small to medium-sized lymphocyte with an eccentric, oval nucleus, heavily condensed chromatin, and intensely basophilic cytoplasm with a prominent perinuclear halo resembling a plasma cell.
Downey Type II (Classic Infectious Mononucleosis Cell) : Very large, pleomorphic cell with abundant, pale sky-blue cytoplasm that is pliable and "flowing." The cytoplasm scallops and indents around adjacent erythrocytes , displaying characteristic intensified dark blue staining at the cytoplasmic borders / cell periphery .
Downey Type III (Transformed Immunoblast) : Large cell with a round-to-oval nucleus, fine chromatin, and 1 to 2 prominent nucleoli, closely simulating a leukemic lymphoblast.
4. Differential Diagnosis: Leukemoid Reaction vs Chronic Myeloid Leukemia (CML)
A critical diagnostic challenge for the medical technologist is distinguishing a severe, benign reactive hyperleukocytosis ( Leukemoid Reaction ) from a malignant myeloproliferative neoplasm ( Chronic Myeloid Leukemia ):
Diagnostic Parameter Leukemoid Reaction Chronic Myeloid Leukemia (CML)
Etiology Benign reaction to severe bacterial infection, sepsis, severe tissue burns, malignancy Clonal malignant myeloproliferative neoplasm of pluripotent hematopoietic stem cells
Total Leukocyte Count Typically 25 – 50 × 10 9 / L 25\text{--}50 \times 10^9/\text{L} 25 – 50 × 1 0 9 / L (rarely > 50 × 10 9 / L >50 \times 10^9/\text{L} > 50 × 1 0 9 / L ) Markedly elevated: often 50 to > 300 × 10 9 / L 50\text{ to }>300 \times 10^9/\text{L} 50 to > 300 × 1 0 9 / L
Peripheral Smear Differential Left shift primarily to bands and metamyelocytes; myelocytes rare (<5%), blasts virtually absent (0%) Full myeloid maturation spectrum ("myelocyte bulge"): blasts (<10%), promyelocytes, myelocytes, metamyelocytes, bands, segs
- Neutrophil Toxic Triad Prominent : Toxic granulation, Döhle bodies, vacuolation Absent or minimal
- Eosinophils and Basophils Normal or decreased Marked Absolute Basophilia and Eosinophilia (hallmark)
Platelet Count Normal to reactive thrombocytosis Markedly elevated, normal, or decreased; giant dysplastic forms
Splenomegaly Absent or mild Marked to massive splenomegaly
Leukocyte Alkaline Phosphatase (LAP / NAP) Markedly Elevated (>100, often 150-350) Markedly Decreased or Absent (<20, often 0-10)
Cytogenetics / Molecular Negative for Philadelphia chromosome; no BCR-ABL1 Positive: t(9;22)(q34.1;q11.2) generating BCR-ABL1 fusion
The Leukocyte Alkaline Phosphatase (LAP / NAP) Score
Principle : Leukocyte Alkaline Phosphatase is an enzyme present in the secondary granules of maturing granulocytes (myelocytes through mature segmented neutrophils). In fresh capillary blood or heparinized blood smears, LAP hydrolyzes naphthol AS-BI phosphate at alkaline pH; the freed naphthol couples with a diazonium salt (e.g., Fast Red Violet LB), precipitating insoluble colored granules in the cytoplasm.
Scoring (Kaplow Method) : Exactly 100 consecutive mature segmented neutrophils and bands are evaluated and graded from 0 to 4+ based on precipitation intensity and granule density:
0 0 0 : No granules.
1 + 1+ 1 + : Faint, scattered granules occupying < 25 % <25\% < 25% of cytoplasm.
2 + 2+ 2 + : Moderate granule density occupying 25 % to 50 % 25\%\text{ to }50\% 25% to 50% of cytoplasm.
3 + 3+ 3 + : Dense, overlapping granules occupying 50 % to 75 % 50\%\text{ to }75\% 50% to 75% of cytoplasm.
4 + 4+ 4 + : Complete, intense, packed granules obscuring the nucleus.
Calculation : LAP Score = ∑ ( Grade × Number of Cells ) \text{LAP Score} = \sum (\text{Grade} \times \text{Number of Cells}) LAP Score = ∑ ( Grade × Number of Cells ) . Theoretical range is 0 to 400 0\text{ to }400 0 to 400 .
Reference Interval : 20 to 100 20\text{ to }100 20 to 100 .
Clinical Interpretation : Elevated in leukemoid reactions, Polycythemia Vera, third-trimester pregnancy, and oral contraceptive use; profoundly low (<20) in untreated CML and Paroxysmal Nocturnal Hemoglobinuria (PNH).
5. Inherited Non-Malignant Leukocyte Morphologic Anomalies
Inherited leukocyte anomalies represent benign or clinically severe genetic mutations affecting white blood cell structural proteins, granules, or nuclear morphogenesis. INHERITED LEUKOCYTE ANOMALIES
- ┌───────────────────────┐ ┌───────────────────────┐ ┌───────────────────────┐
- │ PELGER-HUËT │ │ MAY-HEGGLIN │ │ CHÉDIAK-HIGASHI │
- └───────────┬───────────┘ └───────────┬───────────┘ └───────────┬───────────┘
- │ │ │
- ▼ ▼ ▼
- Bilobed "pince-nez" or • Spindle Döhle-like • Giant lysosomal granules
round unsegmented nuclei. inclusions (MYH9). in all granulated cells.
• LBR gene mutation. • Giant platelets + • LYST gene mutation.
• Normal neutrophil thrombocytopenia. • Albinism, recurrent
function (benign). • Mild bleeding tendency. pyogenic infections.
1. Pelger-Huët Anomaly
Genetics : Autosomal dominant mutation in the Lamin B Receptor ( L B R LBR L BR ) gene on chromosome 1q41-q43, responsible for inner nuclear envelope heterochromatin anchoring.
Morphology : Failure of normal nuclear segmentation. Neutrophils exhibit coarse, hyper-condensed chromatin with hyposegmented nuclei:
Heterozygotes : Classic bilobed "pince-nez" or spectacle-shaped nuclei connected by a thin chromatin filament, or dumbbell-shaped unsegmented nuclei. Over 70 % to 95 % 70\%\text{ to }95\% 70% to 95% of neutrophils display this morphology.
Homozygotes : Complete failure of segmentation, with 100% of neutrophils exhibiting round, ovoid, or peanut-shaped single nuclei ("Stodtmeister" cells).
Clinical Correlation : Completely benign condition; neutrophil migration, phagocytosis, and bactericidal kinetics are fully intact.
Pseudo-Pelger-Huët Anomaly (Acquired) : Acquired hyposegmentation observed in Myelodysplastic Syndromes (MDS) , Acute Myeloid Leukemia (AML), or drug reactions (taxanes, valproic acid). Distinguished by hypogranular cytoplasm, mixed blast populations, and presence in < 50 % <50\% < 50% of neutrophils.
2. May-Hegglin Anomaly
Genetics : Autosomal dominant mutation in the M Y H 9 MYH9 M Y H 9 gene on chromosome 22q12.3, encoding non-muscle myosin heavy chain IIA.
Diagnostic Triad :
Döhle-Like Inclusions : Large ( 2 – 5 μ m 2\text{--}5\ \mu\text{m} 2 – 5 μ m ), spindle-shaped, crescent, or rod-like pale blue cytoplasmic inclusions in neutrophils, eosinophils, and monocytes. Ultrastructurally, these are composed of parallel arrays of non-muscle myosin filaments (distinct from the rough ER of true reactive Döhle bodies).
Giant Thrombocytes (Macrothrombocytes) : Circulating platelets exceeding red cell diameter ( > 7 μ m >7\ \mu\text{m} > 7 μ m ), often hypogranular.
Thrombocytopenia : Variable quantitative platelet reduction ( 40 – 80 × 10 9 / L 40\text{--}80 \times 10^9/\text{L} 40 – 80 × 1 0 9 / L ) leading to mild bleeding diatheses.
3. Chédiak-Higashi Syndrome
Genetics : Rare, severe autosomal recessive mutation in the L Y S T LYST L Y ST (Lysosomal Trafficking Regulator) gene on chromosome 1q42.1-q42.2. Impairs vesicle fusion and fission.
Cytomorphology : Presence of massive, giant, peroxidase-positive lysosomal granules in all granule-containing cells—neutrophils, eosinophils, basophils, monocytes, lymphocytes, and melanocytes.
Pathophysiology : Defective lysosomal trafficking prevents phagosomes from fusing with lysosomes to form phagolysosomes. While ingestion is normal, degranulation and bacterial killing are severely impaired.
Clinical Manifestations : Severe, recurrent, life-threatening pyogenic bacterial infections; partial oculocutaneous albinism (abnormal melanin packaging); progressive peripheral neuropathy; and early transformation into a fatal accelerated phase (hemophagocytic lymphohistiocytosis with pancytopenia and multi-organ failure).
4. Alder-Reilly Anomaly
Genetics : Autosomal recessive lysosomal storage disorders caused by deficiency of specific enzymes degrading mucopolysaccharides (glycosaminoglycans; e.g., Hurler syndrome, Hunter syndrome).
Morphology : Presence of prominent, large, dark purple-red or lilac azurophilic granules ( Reilly bodies ) in the cytoplasm of ALL white blood cell lineages (neutrophils, eosinophils, basophils, monocytes, and lymphocytes).
Diagnostic Staining : Granules stain metachromatically purple with Toluidine Blue , confirming mucopolysaccharide content.
Distinction from Toxic Granulation : Toxic granulation is transient, restricted exclusively to neutrophils, and accompanied by Döhle bodies and toxic vacuoles; Alder-Reilly granulation is permanent, affects all leukocyte lineages including lymphocytes, and features normal leukocyte functional bactericidal activity.